Lumos Diagnostics partners with WellStreet Urgent Care to advance FebriDx reimbursement in U.S. скачать в хорошем качестве

Lumos Diagnostics partners with WellStreet Urgent Care to advance FebriDx reimbursement in U.S.

Lumos Diagnostics Senior Vice President Paul Kase joined Steve Darling from Proactive to discuss a major milestone for the company — the signing of an agreement with WellStreet Urgent Care to accelerate testing and reimbursement pathways for its FebriDx® rapid host-response test. The initiative will be launched through WellStreet’s joint venture with Piedmont Urgent Care in Atlanta, Georgia, marking a key step toward broader US adoption. Under the program, FebriDx will be deployed at a Piedmont Urgent Care site handling approximately 50 respiratory-infection patients per day, providing Lumos with high-quality operational data on workflow efficiency, patient outcomes, and payer engagement. Kase explained that WellStreet will procure FebriDx through PHASE Scientific and submit reimbursement claims for each test, while Pro-spectus will oversee billing data management and claims analysis. This collaborative approach is designed to generate real-world evidence to support the development of comprehensive reimbursement and coverage policies with major U.S. insurers. Pending the granting of a CLIA waiver for FebriDx, Lumos and WellStreet plan to expand the program nationwide, leveraging insights from the pilot to guide a potential rollout across more than 140 WellStreet urgent care locations across the United States. Kase added, “This partnership represents a major step in bringing FebriDx to scale in the U.S. healthcare system. By validating operational efficiency and demonstrating reimbursement viability, we’re building the foundation for widespread clinical adoption of a test that helps physicians quickly differentiate between bacterial and viral infections.” #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #LumosDiagnostics #FebriDx #PointOfCareTesting #HealthcareInnovation #UrgentCare #DiagnosticTesting #InfectionDetection #AntibioticStewardship #MedicalTechnology #ProactiveInvestors